PRTC
$16.41
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-20...
Recent News
PureTech Health plc (LON:PRTC) is favoured by institutional owners who hold 73% of the company
Key Insights Significantly high institutional ownership implies PureTech Health's stock price is sensitive to their...
PureTech Health Completes End-of-Phase 2 Meeting With FDA for Deupirfenidone to Treat Idiopathic Pulmonary Fibrosis
PureTech Health (PRTC) said Monday that it completed the end-of-phase 2 meeting with the US Food and
What Makes PureTech Health (PRTC) a New Buy Stock
PureTech Health (PRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PureTech forms respiratory spin-off Celea to advance deuterated pirfenidone
Celea Therapeutics, the latest spinoff created by PureTech, was created to progress the latter’s lead IPF programme, deupirfenidone.
PureTech launches new biotech built around lung disease drug
The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for idiopathic pulmonary fibrosis.